$363 Million is the total value of Avoro Capital Advisors LLC's 31 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ALIM | Exit | ALIMERA SCIENCES INC | $0 | – | -81,372 | -100.0% | -0.16% | – |
BIOL | Exit | BIOLASE INC | $0 | – | -690,000 | -100.0% | -0.54% | – |
RXDX | Exit | IGNYTA INC. | $0 | – | -200,772 | -100.0% | -0.77% | – |
TROV | Exit | TROVAGENE INC | $0 | – | -323,728 | -100.0% | -0.85% | – |
CNDO | Exit | CORONADO BIOSCIENCES INC | $0 | – | -600,000 | -100.0% | -0.89% | – |
TXMD | Exit | THERAPEUTICS MD INC | $0 | – | -392,000 | -100.0% | -0.91% | – |
CCXI | Exit | CHEMOCENTRYX - INC | $0 | – | -323,607 | -100.0% | -0.94% | – |
Exit | EXELIXIS INC EXEL 20190815 4.250000%notes | $0 | – | -4,250,000 | -100.0% | -1.24% | – | |
SGMO | Exit | SANGAMO BIOSCIENCES INC | $0 | – | -244,199 | -100.0% | -1.47% | – |
QURE | Exit | UNIQURE N V | $0 | – | -226,456 | -100.0% | -2.11% | – |
STML | Exit | STEMLINE THERAPEUTICS - INC | $0 | – | -475,000 | -100.0% | -2.64% | – |
TARO | Exit | TARO PHARMACEUTICAL INDUSshares | $0 | – | -53,800 | -100.0% | -2.91% | – |
EBS | Exit | EMERGENT BIOSOLUTIONS INC | $0 | – | -330,635 | -100.0% | -3.65% | – |
Exit | CELGENE CORP. | $0 | – | -148,800 | -100.0% | -6.58% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
ARGENX SE | 26 | Q3 2023 | 9.5% |
IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-06-14 |
13F-HR | 2024-05-15 |
SC 13G/A | 2024-04-23 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.